Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Emerging treatments for major depression.

Trevor R Norman1, Graham D Burrows

  • 1University of Melbourne, Department of Psychiatry, Austin Hospital, Heidelberg 3084, Victoria, Australia. trevorrn@unimelb.edu.au

Expert Review of Neurotherapeutics
|February 9, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Adjunctive Docosahexaenoic Acid in Residual Symptoms of Depression and Anxiety.

Journal of clinical psychopharmacology·2023
Same author

Letters to the Editor: Author reply to Letters to the Editor regarding 'A challenge to the dopamine orthodoxy in schizophrenia?'

The Australian and New Zealand journal of psychiatry·2023
Same author

A challenge to the dopamine orthodoxy in schizophrenia?

The Australian and New Zealand journal of psychiatry·2023
Same author

Psilocybin in neuropsychiatry: a review of its pharmacology, safety, and efficacy.

CNS spectrums·2022
Same author

Diagnostic agreement and concordance between consultation-liaison psychiatry and non-psychiatric (medical and surgical) doctors: changes within junior doctor's terms.

Australasian psychiatry : bulletin of Royal Australian and New Zealand College of Psychiatrists·2022
Same author

Desvenlafaxine in the treatment of major depression: an updated overview.

Expert opinion on pharmacotherapy·2021

New antidepressant drugs aim to improve efficacy and safety beyond current medications. Research explores novel compounds targeting various biological pathways, with some showing promise in clinical and preclinical studies for depression treatment.

Area of Science:

  • Pharmacology and Psychiatry
  • Neuroscience and Drug Development

Background:

  • Established antidepressant medications, while effective, possess notable limitations.
  • There is a continuous need for novel antidepressant agents with improved efficacy, tolerability, and safety profiles.
  • Current research focuses on developing new molecules to address the shortcomings of existing treatments.

Purpose of the Study:

  • To review emerging compounds with potential antidepressant properties.
  • To assess the developmental stage and preclinical/clinical evidence for these novel agents.
  • To highlight diverse pharmacological approaches beyond traditional monoamine-based mechanisms.

Main Methods:

  • Review of compounds that have undergone clinical trials (e.g., agomelatine, duloxetine).

Related Experiment Videos

  • Examination of preclinical data from validated animal models for compounds yet to enter clinical trials.
  • Analysis of novel targets including cortisol secretion pathways, substance P, vasopressin, neuropeptide Y, and glutamatergic transmission.

    • Main Results:

    • Agomelatine and duloxetine demonstrate antidepressant efficacy in clinical trials.
    • Cortisol-blocking agents (synthesis inhibitors, CRF, and glucocorticoid receptor antagonists) show promise.
    • Neuropeptide antagonists (substance P, vasopressin, neuropeptide Y) represent alternative mechanisms, with mixed developmental outcomes.
    • Glutamatergic transmission modulators show potential based on animal models, awaiting clinical evaluation.

    Conclusions:

    • Several novel compounds and therapeutic strategies are under investigation for antidepressant potential.
    • Future assessment of these agents requires long-term outcome data and post-marketing surveillance.
    • The ultimate superiority of new antidepressants over existing ones remains to be determined.